Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=funder" }, "data": [ { "type": "Grant", "id": "11729", "attributes": { "award_id": "1R01HL169974-01", "title": "Mechanistic modeling of the innate immune responses of the human lung to understand the inter-individual heterogeneity of COVID-19 pneumonia", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22653, "first_name": "EMMANUEL FRANCK", "last_name": "Mongodin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2027-06-30", "award_amount": 762062, "principal_investigator": { "id": 27599, "first_name": "REINHARD", "last_name": "LAUBENBACHER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27600, "first_name": "Borna", "last_name": "Mehrad", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 158, "ror": "https://ror.org/02y3ad647", "name": "University of Florida", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "A key feature of the COVID-19 infection is the vast inter-individual heterogeneity in the severity of the infection. The complex biological mechanisms that underlie this variability remain mostly obscure. We propose to provide a mechanistic understanding of this susceptibility by leveraging 3 key innovations: First, we have developed a 3-dimensional lung culture system that allows for detailed interrogation of the early events in SARS-CoV-2 infection. Second, we have established an animal model of COVID-19 in mice transgenic for the human ACE2 receptor in our facility. Third, we have built a multi-scale mathematical model of lung infection in COVID-19, that we now seek to expand and personalize to individual hosts. We have two Aims in this project: In Aim 1, we will validate, expand, and personalize our existing multi-scale model, using an unbiased approach to identify and test hypotheses relating to susceptibility to severe COVID-19, and in Aim 2 we will test a specific hypothesis regarding the mechanism of the observed inter-individual heterogeneity in COVID-19 severity, namely that it is, in part, mediated by divergent activation of the mTOR pathway in type I alveolar epithelial cells. If successful, this project will identify the biological basis of the immune pathways that result in heterogeneous outcome of COVID-19, paving the way for personalized, host-specific interventions to improve the outcome of the infection.", "keywords": [ "2019-nCoV", "3-Dimensional", "ACE2", "Affect", "Animal Model", "Biological", "COVID-19", "COVID-19 pneumonia", "COVID-19 severity", "Cell Death", "Cells", "Cessation of life", "Complex", "Computer Models", "Confocal Microscopy", "Cryopreservation", "Data", "Disparate", "Engineering", "Epidemiologic Factors", "Epithelial Cells", "Event", "FRAP1 gene", "Flow Cytometry", "Genetic Transcription", "Goals", "Grant", "Heterogeneity", "Human", "Immune", "Immune response", "Immunity", "Immunology", "Individual", "Infection", "Innate Immune Response", "Interferon Type I", "Intervention", "K-18 conjugate", "Literature", "Lung", "Lung infections", "Measurement", "Mediating", "Minor", "Modeling", "Molecular", "Mus", "Outcome", "Pathway interactions", "Persons", "Phosphoproteins", "Predictive Factor", "Predisposition", "Production", "Protocols documentation", "Public Health", "Publishing", "Reproducibility", "Risk", "Role", "SARS-CoV-2 infection", "Sampling", "Severities", "Signal Transduction", "Structure of parenchyma of lung", "Surgical Models", "System", "Testing", "Time", "Tissue Donors", "Tissue Preservation", "Tissues", "Transgenic Mice", "Transgenic Organisms", "Viral", "Virus", "Work", "alveolar epithelium", "base", "biobank", "cohort", "cytokine", "digital twin", "effective therapy", "improved outcome", "individual variation", "innovation", "mTOR inhibition", "mathematical model", "mouse model", "multi-scale modeling", "novel", "outcome prediction", "pandemic disease", "population based", "receptor", "response", "severe COVID-19", "therapeutic target", "three dimensional cell culture", "tool", "virology" ], "approved": true } }, { "type": "Grant", "id": "11730", "attributes": { "award_id": "1R01MH134487-01", "title": "COVID-19, Inflammation and HPA axis activity, and Risk for Psychopathology in Youth", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 8692, "first_name": "Ashley", "last_name": "Smith", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2028-05-31", "award_amount": 794774, "principal_investigator": { "id": 27601, "first_name": "Nadine M.", "last_name": "Melhem", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "There has been an unprecedented mental health crisis and a surge in suicidal thoughts and behaviors (STBs) among youth that predated and was further exacerbated by the pandemic. Studies show that youth are at increased risk for incident treatment for psychiatric diagnosis 1-6 months following COVID-19 infection. Risk for STBs is also increased among individuals with infections; and cognitive impairment following COVID-19 is reported even ~4 months following infection. In addition to the increased morbidity and mortality, the mitigation efforts put in place to reduce transmission resulted in additional stressors on children and families (e.g., parental job loss, parental death, online schooling) and these were associated with increased rates of psychopathology in youth. However, we have a limited understanding of the unique contribution of COVID-19 infection on incidence of psychopathology in youth and the biological mechanisms implicated in risk. Dysregulations in immune responses, specifically, increased IL-6, IL-1b, C-Reactive Protein (CRP), and TNF-a and their mRNA and low cortisol are common biological mechanisms implicated in COVID-19 severity and in psychopathology. Our goals are to examine the impact of COVID-19 infection on incidence of psychopathology in youth; its impact on inflammation and HPA axis markers; and to identify clinical, cognitive, biological, and psychosocial characteristics that will help predict youth at risk for onset of psychopathology following COVID-19 infection. We propose to recruit youth, aged 12-17 years, without history of psychiatric disorders or chronic Illness or chronic infections who were: 1) infected with COVID-19 within the past month (COVID, n=200); 2) without history of COVID-19, influenza (IFV), or any respiratory infections in the past 6 months (no-COVID, n=200); and 3) youth with IFV within the past month (IFV, n=100). The IFV group will allow us to examine whether COVID-19 or infections in general are associated with risk. Participants will be followed at 3, 6, and 18 months after baseline and assessed on psychiatric and physical symptoms, cognitive function, incident psychopathology; pandemic and non-pandemic stressors; and risk and protective factors at all timepoints. At baseline, 3, and 6 months, we will measure inflammation (cytokines, mRNA for inflammatory genes); and collect acute and chronic HPA axis activity measures (hair cortisol concentrations, salivary cortisol). We hypothesize that the COVID group will show increased risk of onset of psychopathology, specifically depression and anxiety disorders and STBs, compared to the no-COVID and IVF groups. They will also show increased inflammation and psychiatric and physical symptoms over time; and reduced HPA axis activity and cognitive function over time; and these will in turn predict onset of psychopathology. This study will advance our understanding of the impact of COVID-19 infection on risk for psychopathology in youth and the biological mechanisms implicated in risk. The results will also extend to other types of infections. This study is essential to inform our preparedness efforts for future epidemics and pandemics, which are inevitable and on the rise.", "keywords": [ "Acute", "Adolescent", "Adult", "Age", "Antibodies", "Anxiety Disorders", "Biological", "Biological Markers", "Blood", "C-reactive protein", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 severity", "Cessation of life", "Characteristics", "Child", "Chronic", "Chronic Disease", "Clinical", "Cognitive", "Data", "Development", "Domestic Violence", "Emerging Communicable Diseases", "Family", "Family history of", "Feeling suicidal", "Frequencies", "Genes", "Goals", "Hair", "Hydrocortisone", "Immune response", "Impaired cognition", "Incidence", "Individual", "Infection", "Inflammation", "Inflammatory", "Influenza", "Interleukin-6", "Intervention", "Job loss", "Measures", "Mental Depression", "Mental Health", "Mental disorders", "Messenger RNA", "Monitor", "Morbidity - disease rate", "Participant", "Psychiatric Diagnosis", "Psychiatric therapeutic procedure", "Psychopathology", "Public Health", "Race", "Readiness", "Recording of previous events", "Reporting", "Respiratory Tract Infections", "Risk", "Risk Factors", "SARS-CoV-2 infection", "Salivary", "Schools", "Severities", "Socioeconomic Status", "TNF gene", "Testing", "Time", "Vaccination", "Youth", "aged", "chronic infection", "cognitive function", "coronavirus disease", "cytokine", "future epidemic", "future pandemic", "high risk", "hypothalamic-pituitary-adrenal axis", "improved", "mortality", "novel therapeutic intervention", "pandemic disease", "pandemic impact", "physical symptom", "post SARS-CoV-2 infection", "protective factors", "psychiatric symptom", "psychosocial", "recruit", "sex", "stressor", "suicidal behavior", "suicidal risk", "transmission process" ], "approved": true } }, { "type": "Grant", "id": "11731", "attributes": { "award_id": "1R21DC021260-01", "title": "Defining the molecular and anatomical basis of the blood-olfactory barrier (BOB)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Deafness and Other Communication Disorders (NIDCD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6520, "first_name": "SUSAN L.", "last_name": "SULLIVAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2025-06-30", "award_amount": 433879, "principal_investigator": { "id": 27602, "first_name": "E. Ashley", "last_name": "Moseman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The upper respiratory tract is lined by two distinct types of epithelium. Respiratory epithelium humidifies and modulates incoming air temperature as it passes toward the lungs. Olfactory epithelium on the other hand is specialized for chemosensation and supports detection of airborne odorants by olfactory sensory neurons (OSNs). We have recently described that blood vessels within the olfactory mucosa form a “blood -olfactory barrier” (BOB) that prevents high molecular weight blood borne proteins from accessing the olfactory tissues. This BOB effectively isolates olfactory tissues from blood borne molecules in much the same way that the blood brain barrier and the blood retinal barrier function in the brain and eye. In our studies we found that antibodies (~150kD) against viral pathogens cannot exit the blood to prevent infections within the olfactory epithelium. The existence of the BOB may help reconcile years of seemingly contradictory upper airway immunity data, and also helps explain why pathogens such as SARS-CoV-2 that infect the olfactory epithelium cause “breakthrough infections” when blood antibody titers are high. We know very little about the basic cellular and molecular building blocks of this newly defined vascular barrier. This proposal will establish the limits of BOB homeostatic permeability and several foundational insights about the BOB, including: BOB functionality from developmental stages until late adulthood, determine the cellular and junctional makeup that generates the BOB, define the functional permeability limits during health and inflammation, and finally determine the role of olfactory neurons in orchestrating olfactory barrier identity.", "keywords": [ "2019-nCoV", "Ablation", "Adult", "Age", "Aging", "Air", "Anatomy", "Animals", "Anosmia", "Antibodies", "Antibody titer measurement", "Astrocytes", "Binding", "Biology", "Blood", "Blood - brain barrier anatomy", "Blood Proteins", "Blood Vessels", "Blood-Retinal Barrier", "Brain", "Cells", "Central Nervous System", "Central Nervous System Agents", "Clinical Treatment", "Complex", "Data", "Detection", "Development", "Disease", "Drug Delivery Systems", "Electron Microscopy", "Endothelial Cells", "Endothelium", "Epithelial", "Esthesia", "Exclusion", "Eye", "Genetic Transcription", "Goals", "Health", "Health system", "Host Defense", "Immune", "Immunity", "Infection prevention", "Inflammation", "Inflammation Mediators", "Inflammatory", "Invaded", "Knowledge", "Lung", "Lung diseases", "Maintenance", "Microscopy", "Molecular", "Molecular Weight", "Movement", "Nasal turbinate bone structure", "Neurons", "Nose", "Olfactory Epithelium", "Olfactory Mucosa", "Organ", "Pericytes", "Permeability", "Plasma Proteins", "Proteins", "Publishing", "Regulation", "Role", "Temperature", "Tight Junctions", "Tissues", "Toxin", "Upper respiratory tract", "Vaccine Design", "Vascular Endothelial Cell", "Work", "airway epithelium", "breakthrough infection", "cell growth regulation", "empowerment", "expectation", "genetic approach", "insight", "microbial", "novel", "olfactory sensory neurons", "pathogen", "pathogenic virus", "perineural", "prevent", "respiratory", "solute", "transcriptomics", "vaccinology" ], "approved": true } }, { "type": "Grant", "id": "11732", "attributes": { "award_id": "1K01AR082964-01", "title": "Investigating the Impact of Social Isolation on Bone Metabolism", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 24193, "first_name": "Kristy", "last_name": "Nicks", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2028-06-30", "award_amount": 127427, "principal_investigator": { "id": 27603, "first_name": "Rebecca", "last_name": "Mountain", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1417, "ror": "https://ror.org/017xncd55", "name": "MaineHealth", "address": "", "city": "", "state": "ME", "zip": "", "country": "United States", "approved": true }, "abstract": "Social isolation is a potent form of psychosocial stress, and a growing public health concern. Older adults, particularly those individuals isolated during the COVID-19 pandemic, are particularly vulnerable. One in four individuals over the age of 65 are estimated to be affected by social isolation and loneliness, which are associated with an increase in mortality risk by up to 70%. Previous studies have shown other forms of psychosocial stress and mental illness are associated with increased risk for osteoporosis and related fractures, which are likewise associated with increased mortality in older adults. Despite the increase in social isolation and the overlap between at-risk populations, there has been little research on the effects of social isolation on bone loss and skeletal metabolism. The limited work that has been done in rodents suggest that social isolation negatively impacts bone health, leading to decreased bone mineral density. None of these studies, however, have explored the mechanisms of isolation-induced bone loss, or examined differences in the effect of isolation on bone between the sexes. My own preliminary studies show that males exposed to social isolation had reduced femoral bone volume fraction, bone mineral density, and cortical thickness. Females, conversely, did not have any reduction in bone mass. My data also showed changes to glucocorticoid receptor and β2 adrenergic receptor expression as a result of social isolation, which both have known effects on bone. The goal of this project is therefore to test the overarching hypothesis that social isolation leads to bone loss through altered glucocorticoid (Aim 1) and sympathetic nervous system (Aim 2) activity. I will test these hypotheses using a 4 to 8-week-long mouse model of social isolation in 16-week old mice, in combination of pharmacological and genetic approaches. I will also use proteomic and microRNA sequencing approaches to identify novel systemic changes in response to social isolation that may impact bone. The proposed project will be the first study to identify mediating mechanisms of social isolation-induced bone loss and precisely test the effects of isolation on bone metabolism through a range of imaging, genetic, histologic, and omic approaches. The results of this project will inform future clinical and epidemiological studies, and help identify prevention strategies and treatments for individuals at the greatest risk for social isolation.", "keywords": [ "11-beta-Hydroxysteroid Dehydrogenases", "Adrenergic Agents", "Affect", "Anxiety", "Architecture", "Biological Markers", "Bone Density", "Bone Marrow", "Bone Resorption", "Brain", "COVID-19 pandemic", "Catecholamines", "Clinical", "Clinical Research", "Clinical Treatment", "Corticosterone", "Data", "Disease", "Elderly", "Exposure to", "Female", "Femur", "Fracture", "Future", "Gene Expression", "Genes", "Genetic", "Glucocorticoid Receptor", "Glucocorticoids", "Goals", "Health", "Histologic", "Homeostasis", "Human", "Image", "Individual", "Knockout Mice", "Loneliness", "Long-Term Effects", "Measures", "Mediating", "Mental Depression", "Mental Health", "Mental disorders", "Metabolic", "Metabolism", "Metyrapone", "MicroRNAs", "Modeling", "Molecular", "Morbidity - disease rate", "Mus", "NADH dehydrogenase (ubiquinone)", "Osteogenesis", "Osteoporosis", "Outcome", "Phase", "Phenotype", "Physiological", "Populations at Risk", "Prevalence", "Prevention strategy", "Propranolol", "Proteomics", "Psyche structure", "Psychosocial Stress", "Public Health", "Research", "Risk", "Rodent", "Role", "Serum", "Sex Differences", "Signal Transduction", "Social isolation", "Stress", "Sympathetic Nervous System", "Testing", "Thick", "Time", "Work", "antagonist", "beta-2 Adrenergic Receptors", "biological sex", "bone", "bone health", "bone loss", "bone mass", "bone metabolism", "circulating microRNA", "coping", "epidemiology study", "experience", "fracture risk", "genetic approach", "human old age (65+)", "inhibitor", "male", "miRNA expression profiling", "mortality", "mortality risk", "mouse model", "neural", "novel", "pharmacologic", "prevent", "receptor", "receptor expression", "response", "sex", "skeletal", "stress disorder", "substantia spongiosa", "therapeutic target", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "11733", "attributes": { "award_id": "1R21AI178133-01", "title": "Mechanisms of macrophage death co-dependent on M. tuberculosis and IFN-a,b receptor", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6515, "first_name": "Katrin", "last_name": "Eichelberg", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2025-06-30", "award_amount": 254250, "principal_investigator": { "id": 27604, "first_name": "CARL Francis", "last_name": "NATHAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Mycobacterium tuberculosis (Mtb) was the world’s single leading cause of death from infection before COVID- 19. Direct-acting antimycobacterial regimens are long, often toxic and plagued by emergence of drug resistance. Adjunctive therapies could potentially speed the cure of tuberculosis by targeting a process in the host that alters the host-pathogen interaction to the advantage of the host. One potential form of host-directed therapy would be to help macrophages better survive Mtb infection. In vitro, the death of Mtb-infected mouse macrophages is co- dependent on a type I interferon (IFN), IFN-beta, that macrophages produce in response to Mtb, along with an additional contribution by Mtb. This application seeks to identify specific molecular participants in Mtb-induced macrophage death that are downstream of the type I IFN receptor. We have identified potential molecular participants by two approaches—a CRISPR activation screen that restored Mtb-induced cell death to macrophages lacking the type I IFN receptor, and an innovative biochemical pulldown approach using a probe based on a small chemical compound that rescues Mtb-infected macrophages from Mtb-induced cell death without impairing the growth of Mtb. This application aims to validate the candidates genetically, test the ability of already existing inhibitors to recapitulate the effect of knocking them out, and then place the validated candidates on a mechanistic path. That would set the stage for future studies, beyond the scope of this application, to find, improve or develop drug-like inhibitors for tests in preclinical models of TB to see if they mitigate pathology and hasten cure when used in combination with direct-acting antimycobacterial agents.", "keywords": [ "Aconitic Acid", "Animal Model", "Antibiotics", "Antimycobacterial Agents", "Apoptosis", "Binding", "Biochemical", "Biogenesis", "COVID-19", "CRISPR-mediated transcriptional activation", "Carboxy-Lyases", "Cathepsins", "Cause of Death", "Cell Death", "Cell Death Induction", "Cell Line", "Cells", "Cessation of life", "Chemicals", "Cods", "Drug resistance", "Enzymes", "Future", "G-Protein-Coupled Receptors", "GPR84 gene", "Genes", "Genetic", "Goals", "Growth", "IFNAR1 gene", "Immune Response Genes", "Impairment", "In Vitro", "Individual", "Infection", "Inflammation", "Interferon Type I", "Interferon alpha", "Interferon-beta", "Learning", "Link", "Lysosomes", "Mediating", "Medium chain fatty acid", "Molecular", "Monoclonal Antibodies", "Mus", "Mycobacterium tuberculosis", "Necrotic Lesion", "Orphan", "Participant", "Pathology", "Pathway interactions", "Peptide Hydrolases", "Pharmaceutical Preparations", "Pre-Clinical Model", "Process", "Proteins", "Regimen", "Resistance", "Role", "Signal Transduction", "Speed", "Testing", "Tuberculosis", "Virulent", "Virus", "activating transcription factor", "bactericide", "candidate identification", "candidate validation", "cytokine", "drug-like compound", "experimental study", "gene product", "genetic approach", "improved", "inhibitor", "innovation", "lysosomal Pro-X carboxypeptidase", "macrophage", "overexpression", "pathogen", "receptor", "response", "success", "transcription factor", "tuberculosis treatment", "type I interferon receptor" ], "approved": true } }, { "type": "Grant", "id": "11734", "attributes": { "award_id": "1R01AI176554-01", "title": "Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 23961, "first_name": "Zuoyu", "last_name": "Xu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2028-06-30", "award_amount": 1027000, "principal_investigator": { "id": 27605, "first_name": "Angela", "last_name": "Meier", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27606, "first_name": "Victor", "last_name": "Nizet", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 27607, "first_name": "Liangfang", "last_name": "Zhang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Pneumonia is the most common cause of hospitalization due to infection in the US and the most common cause of infection-related death. Mortality in healthcare-associated pneumonia (HAP) is 13% overall and 36% in patients admitted to the ICU. Bacterial lung infections are also a frequent complication of prolonged mechanical ventilation required in patients after major surgery, traume, and severe lung injury due to viral pneumonias (e.g. SARS-Cov2); mortality in such ventilator-associated pneumonias (VAP) is even more grave. Two leading bacterial causes of HAP/VAP are the Gram-negative nosocomial pathogens Pseudomonas aeruginosa (PA) and Acinetobacter baumannii (AB), both frequently highly multidrug-resistant and can develop resistance to last line carbapenems. Gram-negative bacterial HAP/VAP is frequently complicated by neutrophil- and cytokine driven hyperinflammation and associated lung damage—which when severe is designated “acute respiratory distress syndrome” (ARDS). There are no standard clinically proven therapies to support the host immune system in clearing severe bacterial pneumonia while simultaneously suppressing the hyperinflammation that leads to lung tissue destruction. Here we describe a highly innovative drug concept for critically ill patients with severe PA and AB pneumonia with a unique multifold mechanism of action: biomimetic human macrophage membrane-coated nanoparticles (MΦ-NP). MΦ-NP are made by wrapping cell membranes derived from human macrophages around biodegradable polymeric cores, retaining their membrane lipid bilayer and full repertoire of surface structures and receptors, just on a nano (~1/50,000th) scale. The natural biomimicry imparts to the MΦ-NP the ability to bind, sequester and neutralize bacterial toxins, lipopolysaccharide (LPS), and host-derived proinflammatory cytokines, a tripartite mechanism of action to curb harmful inflammation, preserved tissue integrity, and facilitate bacterial clearance. Here we describe our extensive prior published and preliminary results that strongly support the novel therapeutic concept of MΦ-NP for the treatment of severe Gram- bacterial pneumonia in ICU patients, and how the proven team at San Diego-based Cellics Therapeutics will support our Clinical Development Plan at every step of the pathway toward an investigational new drug (IND) application and entry into Phase 1 clinical trials to meet this critical unmet medical need. In Aim 1 we will study the capacity of MΦ-NP to preserve lung epithelial and endothelial barrier integrity and function upon pneumonia challenge, including work in novel 3D human iPSC derived organoids. In Aim 2, we will examine the ability of MΦ-NP to block excessive alveolar macrophage and neutrophil-driven inflammation but preserve their antibacterial function against MDR Gram- pathogens. Finally in Aim 3, we will conduct in vivo analysis of the benefits of intratracheal (IT) and/or intravenous (IV) MΦ-NP therapy on mortality, bacterial clearance, and lung inflammation/damage in murine models of MDR Gram- pneumonia and perform key studies to assess PK/PD and toxicity profile of MΦ-NP administration.", "keywords": [ "2019-nCoV", "3-Dimensional", "Acinetobacter baumannii", "Acinetobacter baumannii pneumonia", "Acute Respiratory Distress Syndrome", "Alveolar Macrophages", "Anti-Bacterial Agents", "Antibiotics", "Antimicrobial Resistance", "Apoptosis", "Bacterial Pneumonia", "Bacterial Toxins", "Binding", "Biomimetics", "Blood donor", "Brain Injuries", "Carbapenems", "Caring", "Cell membrane", "Cessation of life", "Clinical", "Clinical Management", "Complication", "Confined Spaces", "Critical Illness", "Development Plans", "Drug Kinetics", "Endothelial Cells", "Endothelium", "Epithelial", "Epithelial Cells", "Goals", "Hospital Mortality", "Hospitalization", "Hospitals", "Human", "Immune system", "Immunologics", "Infection", "Inflammation", "Inflammatory", "Inflammatory Response", "Inflammatory Response Pathway", "Influenza", "Intensive Care Units", "Intravenous", "Invaded", "Investigational New Drug Application", "Knowledge", "Life", "Lipid Bilayers", "Lipopolysaccharides", "Lung", "Lung infections", "Mechanical ventilation", "Medical", "Membrane", "Morbidity - disease rate", "Multi-Drug Resistance", "Mus", "Nosocomial pneumonia", "Operative Surgical Procedures", "Organism", "Organoids", "Pathway interactions", "Patient Admission", "Patients", "Phagocytosis", "Pharmaceutical Preparations", "Pharmacodynamics", "Phase I Clinical Trials", "Pneumonia", "Production", "Proliferating", "Pseudomonas aeruginosa", "Pseudomonas aeruginosa pneumonia", "Publishing", "Pulmonary Inflammation", "Resistance development", "Respiratory Burst", "Septic Shock", "Serum", "Structure", "Structure of parenchyma of lung", "Surface", "Therapeutic", "Tissue Preservation", "Tissues", "Toxic effect", "Viral Pneumonia", "Work", "biodegradable polymer", "biomaterial compatibility", "cell injury", "clinical development", "cytokine", "cytotoxic", "experience", "extracellular", "immune clearance", "in vivo", "induced pluripotent stem cell", "innovation", "lung injury", "lung preservation", "macrophage", "mortality", "mouse model", "multidrug-resistant Pseudomonas aeruginosa", "nano", "nanoparticle", "nanotherapeutic", "neutrophil", "novel", "novel therapeutics", "particle therapy", "pathogen", "pathogenic bacteria", "pharmacokinetics and pharmacodynamics", "pneumonia model", "preservation", "receptor", "response", "septic", "septic patients", "ventilator-associated pneumonia" ], "approved": true } }, { "type": "Grant", "id": "11735", "attributes": { "award_id": "1R01HL165940-01A1", "title": "The Impact of the COVID-19 Pandemic Environment on Cardiometabolic Health", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 6203, "first_name": "Sean", "last_name": "Coady", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2026-03-31", "award_amount": 304512, "principal_investigator": { "id": 6577, "first_name": "Shivani A", "last_name": "Patel", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "RELEVANCE: The COVID-19 pandemic upended life in the United States through social distancing policies, such as remote work mandates, to halt the spread of the SARS-CoV-2 coronavirus. Weight gain and changes in physical activity, dietary intake, and other health behaviors related to cardio-metabolic conditions were reported during and immediately following the acute lockdown period. Two years after the acute lockdown period, nearly one-third of Americans continue to work remotely and understanding whether these early cardio- metabolic health changes persisted will have important implications for cardio-metabolic health in the decades to come. OBJECTIVES: To quantify the magnitude, modifying characteristics, and mechanisms associated with cardio-metabolic health changes in US adults >1 year after the post-acute lockdown period. DESIGN: We build on a high-quality community-based cohort study of ~140,000 adults, the American Cancer Society Cancer Prevention Study 3 (CPS-3). CPS-3 participants provided detailed health behavior, weight status, medical history, and socioeconomic data at triennial surveys since enrollment (2013). The 2021-22 survey supplements standard modules with information specifically designed to measure individual experiences of the pandemic environment such as changes to work and caregiving responsibilities. We will use geocodes to link individual data with measures of the severity of the local pandemic environment, measured by local policy restrictions, mobility reductions, and epidemiologic risks. We will examine the overall impact of the pandemic environment on weight status and cardio-metabolic health behaviors (dietary intake, physical activity, sedentary time, sleep patterns, tobacco use, and alcohol use). In AIM 1A, we will evaluate the impact of the pandemic environment on changes in weight status and cardio-metabolic health behaviors. In Aim 1B, we will identify population characteristics that modify the pandemic’s impact on changes in cardio-metabolic health. In AIM 2, we will evaluate potential mechanisms linking the pandemic environment and weight status, with special emphasis on remote work policies. IMPACT: This national investigation with prospectively collected ata before and during the pandemic will provide insight into the cardio-metabolic health sequelae of the COVID-19 pandemic. As we move into the post-pandemic recovery phase, findings may inform policy decisions regarding continuation of remote work, as well as future priority areas and priority populations for cardio-metabolic health promotion.", "keywords": [ "2019-nCoV", "Acute", "Adult", "Alcohol consumption", "American", "American Cancer Society", "Area", "Behavior", "Body Weight Changes", "Buffers", "COVID-19 pandemic", "COVID-19 pandemic effects", "Characteristics", "Cohort Studies", "Communities", "Containment", "County", "Data", "Diet", "Dietary intake", "Distress", "District of Columbia", "Dose", "Enrollment", "Environment", "Epidemiology", "Equity", "Ethnic Origin", "Future", "Geography", "Health", "Health Priorities", "Health Promotion", "Health Status", "Health behavior", "Income", "Individual", "Institution", "Investigation", "Job loss", "Life", "Link", "Longitudinal Studies", "Measures", "Mediator", "Medical History", "Natural experiment", "Obesity", "Participant", "Persons", "Phase", "Physical activity", "Policies", "Population", "Population Characteristics", "Population Group", "Psychosocial Factor", "Quarantine", "Race", "Recovery", "Reporting", "Research Support", "Risk", "SARS-CoV-2 infection", "Severities", "Sleep", "Social Distance", "Social isolation", "Socialization", "Socioeconomic Factors", "Surveys", "Time", "Tobacco use", "US State", "Unemployment", "United States", "Urbanicity", "Vaccines", "Weight", "Weight Gain", "Work", "age group", "cancer prevention", "cardiometabolism", "caregiving", "cohort", "data infrastructure", "design", "experience", "improved", "infection risk", "insight", "outcome prediction", "pandemic disease", "pandemic impact", "pandemic response", "post-pandemic", "pre-pandemic", "prospective", "psychosocial", "public database", "public health priorities", "resilience", "response", "sedentary", "sex", "sleep pattern", "social vulnerability", "socioeconomics" ], "approved": true } }, { "type": "Grant", "id": "11736", "attributes": { "award_id": "1R01DK135483-01", "title": "Determining the Incidence, Risk Factors and Biological Drivers of Irritable Bowel Syndrome (IBS) as Part of the Constellation of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Outcomes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [ { "id": 27608, "first_name": "JAN-MICHAEL AXEL", "last_name": "Klapproth", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2028-04-30", "award_amount": 650178, "principal_investigator": { "id": 27609, "first_name": "Kristen M", "last_name": "Pogreba-Brown", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 438, "ror": "https://ror.org/03m2x1q45", "name": "University of Arizona", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "Irritable bowel syndrome (IBS) affects an estimated 10-15% of the U.S population and induces morphologic and physiological abnormalities significantly impairing one’s quality of life and is the most common diagnosis of a heterogeneous group of gastrointestinal disorders of gut-brain interaction (DGBI). The risk of IBS following an acute gastrointestinal (GI) infection is approximately 9%, and has been linked to numerous bacterial, protozoan, and viral infections. Notably, SARS-CoV-2 infection elicits a wide range of GI symptoms, including diarrhea, nausea, and vomiting, with reports of acute GI symptoms occurring in up to 61% of patients. Initial studies have shown persistent GI symptoms lasting up to 5-6 months post-acute infection in 40-44% of SARS-CoV-2 patients. Given the scale of the ongoing pandemic and reports of chronic GI symptoms after acute SARS-CoV-2 infection, determining how this pathogen will impact the incidence or exacerbate IBS symptoms, while playing a major role in the development of post-acute SARS-CoV-2 (PASC), known colloquially as Long COVID, is imperative. However, to date, there is a dearth of studies that have assessed the development of post-acute GI disorders following SARS-CoV-2 infection. The Arizona CoVHORT, an ongoing, prospective, longitudinal study of the acute and long-term impacts of SARS-CoV-2 infection on adults, provides the critical extant infrastructure required to efficiently investigate the health impacts of the pandemic. Using this cohort infrastructure, we propose the following aims: (1) Estimate the incidence of IBS following SARS-CoV-2 infections compared to non- infected participants. To determine the incidence of IBS following SARS-CoV-2 infection, we will employ data from the Rome IV IBS diagnostic questionnaire to compare rates of new onset IBS among participants who tested positive for SARS-CoV-2 to those who did not, while controlling for confounding factors such as age, gender, and ethnicity comorbidities and concomitant stress at the time of infection. (2) Determine the role of pre-existing IBS on the development and severity of PASC. We will follow IBS participants who reported a diagnosis (1) prior to March 2020, (2) before a SARS-CoV-2 infection, and (3) those who report no history of infection to determine their ongoing and long-term symptoms over 2-5 years, including assessment of risk factors and confounders. (3) Establish mechanisms of IBS following SARS-CoV-2 infections including differences in the fecal microbiome composition and function, the host’s anti-commensal immune response to the fecal microbiome, and targeted/untargeted serum protein biomarkers among SARS-CoV-2 exposed and unexposed, who do and do not develop incident IBS. We will collect blood and stool samples and employ shotgun metagenomics, host-microbiome directed IgG-seq and IgA-seq, and high dimensional serum proteomic arrays to explore novel mechanisms, phenotypes, and biomarkers associated with PASC-IBS. PASC will impact the individual health of millions of Americans over the next several years, and to date, limited studies have examined potential long-term effects of SARS-CoV-2 on GI outcomes specifically.", "keywords": [ "2019-nCoV", "Acute", "Adult", "Affect", "Age", "American", "Arizona", "Bacterial Infections", "Biological", "Biological Markers", "Blood specimen", "COVID-19 patient", "Caregivers", "Chronic", "Critical Pathways", "Data", "Development", "Diagnosis", "Diagnostic", "Diarrhea", "Disease Progression", "Enrollment", "Enteric Nervous System", "Ethnic Origin", "Functional Gastrointestinal Disorders", "Gastrointestinal Diseases", "Gender", "Health", "Health Personnel", "Immune response", "Immunoglobulin A", "Immunoglobulin G", "Impairment", "Incidence", "Individual", "Infection", "Infrastructure", "Investigation", "Irritable Bowel Syndrome", "Link", "Long COVID", "Long-Term Effects", "Longitudinal cohort study", "Metagenomics", "Morbidity - disease rate", "Morphology", "Nausea", "Outcome", "Participant", "Pathologic", "Patients", "Persons", "Phenotype", "Physiological", "Play", "Population", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Proteomics", "Protozoan Infections", "Quality of life", "Questionnaires", "Recording of previous events", "Reporting", "Research", "Risk", "Risk Assessment", "Risk Factors", "Role", "Rome", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "SARS-CoV-2 positive", "Serum", "Serum Proteins", "Severities", "Shotguns", "Stress", "Symptoms", "Testing", "Time", "Virus Diseases", "Vomiting", "acute infection", "associated symptom", "cohort", "comorbidity", "disorders of gut-brain interaction", "experience", "fecal microbiome", "gastrointestinal", "gastrointestinal infection", "gastrointestinal symptom", "gut inflammation", "gut microbiome", "high dimensionality", "host microbiome", "infection rate", "long term consequences of COVID-19", "longitudinal prospective study", "microbiome composition", "mortality", "multiple omics", "novel", "novel marker", "pandemic disease", "pandemic impact", "pathogen", "post SARS-CoV-2 infection", "protein biomarkers", "psychologic", "stool sample" ], "approved": true } }, { "type": "Grant", "id": "11737", "attributes": { "award_id": "1U18FD008023-01", "title": "FDA Vet-LIRN Capacity-Building of Ohio ADDL to support rapid testing for COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26272, "first_name": "Megan", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2024-06-30", "award_amount": 40000, "principal_investigator": { "id": 27610, "first_name": "Melanie", "last_name": "Prarat", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2043, "ror": "", "name": "OHIO STATE DEPARTMENT OF AGRICULTURE", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal from the Ohio Department of Agriculture (ODA) is in response to Funding Opportunity Announcement (FOA) PAR-18-604 from the Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) Veterinary Laboratory Investigation and Response Network (Vet-LIRN). This proposal from ODA’s Animal Disease Diagnostic Laboratory (ADDL) addresses the following key project area: 1. Purchase of equipment to build testing capacity of SARS-CoV-2. a. We are requesting funds to support the purchase of a real-time PCR platform budge for SARS-CoV-2 testing of diagnostic samples submitted to the Ohio ADDL. Additionally, participation in additional projects such as method development and/or method validation/improvement and matrix extension work as determined by the VPO may be included in the capacity-building funds. This proposal will increase the capacity of our laboratory to conduct SARS-CoV-2 diagnostic testing for high-throughput sample processing capability and data analysis by maintaining redundancy in testing equipment to reduce any delays in testing due to equipment malfunctions or needed repairs.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11738", "attributes": { "award_id": "1R01DK132225-01A1", "title": "Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [ { "id": 20615, "first_name": "MAREN R", "last_name": "LAUGHLIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2026-06-30", "award_amount": 994162, "principal_investigator": { "id": 25570, "first_name": "Paul", "last_name": "Kievit", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 25571, "first_name": "Charles T", "last_name": "Roberts", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 27611, "first_name": "MARK K", "last_name": "SLIFKA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 27612, "first_name": "DANIEL N", "last_name": "STREBLOW", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 765, "ror": "https://ror.org/009avj582", "name": "Oregon Health & Science University", "address": "", "city": "", "state": "OR", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 global pandemic caused by the novel SARS-CoV-2 coronavirus continues to result in significant morbidity and mortality worldwide. Although effective vaccines and therapeutics have been introduced, COVID-19 will continue to persist as a public health issue as a result of vaccine resistance/hesitancy and risk of reinfection, the emergence of variants of concern that may evade current vaccines, and the potential existence of latent viral reservoirs. The adverse outcomes associated with COVID- 19 are increased by a number of pre-existing conditions, notably diabetes, cardiovascular disease, and hypertension. These conditions share obesity and insulin resistance (IR) as a common underlying feature, which has raised the question of whether obesity per se is an independent risk factor for more severe COVID- 19 outcomes in the absence of clinically diagnosed diabetes, cardiovascular disease, or hypertension. This concept is supported by previously described effects of obesity on respiratory disease and the immune response. Evidence is also accumulating for altered glucose and lipid metabolism and new-onset diabetes in COVID-19 patients that can persist after recovery from acute infection, and that constitutes an important component of post-acute sequelae of COVID-19 (PASC). These data suggest that, while obesity and metabolic disease affect the acute COVID-19, that there are a reciprocal acute and post-acute effects of COVID-19 on metabolic control. We hypothesize that: (1) obesity/IR in the absence of other conditions such as frank diabetes, CVD, or hypertension will increase the severity of SARS-CoV-2 infection and acute disease pathology; and (2) that SARS-CoV-2 infection will exacerbate pre-existing preclinical metabolic disease as reflected in progression to more advanced, clinically evident disease. We propose to address these hypotheses through pursuit of the following specific aims. Specific Aim 1. Determine the effect of pre-existing obesity/IR on the acute response to SARS-CoV-2 infection. Specific Aim 2. Determine the effect of SARS-CoV-2 infection on the post-acute progression of metabolic disease. We will employ a nonhuman primate preclinical model of lean, metabolically healthy and obese, insulin- resistant adult male rhesus macaques infected with SARS-CoV-2 over a 2-week (acute phase) or 6-month (post-acute) course of disease, during which time comprehensive longitudinal assessments of viral load, lung pathology, peripheral and adipose immune cell responses, and glucose and lipid metabolism will be performed. At necropsy following the acute and post-acute studies, islet function will be assessed and multiple tissue samples collected for determination of viral distribution and persistence in potential latent reservoirs. The proposed studies represent a unique opportunity to elucidate the mechanisms underlying the reciprocal relationship between COVID-19 and metabolic disease in an experimentally tractable preclinical model.", "keywords": [ "2019-nCoV", "Acceleration", "Acute", "Acute Disease", "Address", "Adipocytes", "Adipose tissue", "Adult", "Affect", "Alveolar", "Anatomy", "Animals", "Antigens", "Appearance", "Autopsy", "Biological Markers", "Blood", "C-Peptide", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 patient", "COVID-19 risk", "COVID-19 severity", "COVID-19 survivors", "Cardiovascular Diseases", "Cells", "Chronic", "Clinical", "Data", "Diabetes Mellitus", "Disease", "Endocrine", "Endothelial Cells", "Exhibits", "Foundations", "Glucose", "Glycosylated hemoglobin A", "Heart Diseases", "Hospitalization", "Human", "Hyperinsulinism", "Hypertension", "Immune", "Immune response", "Immunohistochemistry", "Impairment", "Individual", "Infection", "Inflammation", "Insulin", "Insulin Resistance", "Irrigation", "Light", "Link", "Lipids", "Lung", "Macaca", "Macaca mulatta", "Metabolic", "Metabolic Control", "Metabolic Diseases", "Metabolism", "Modeling", "Monitor", "Morbidity - disease rate", "Morphology", "Nature", "Newly Diagnosed", "Nucleic Acids", "Obesity", "Oral", "Outcome", "Pancreas", "Pathology", "Patients", "Peripheral", "Phase", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Pre-Clinical Model", "Predisposition", "Public Health", "Pulmonary Pathology", "Quantitative Reverse Transcriptase PCR", "Recovery", "Reporting", "Resistance", "Respiratory Disease", "Respiratory physiology", "Risk", "Risk Factors", "SARS-CoV-2 B.1.617.2", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Sampling", "Serology", "Severities", "Severity of illness", "System", "Testing", "Therapeutic", "Thinness", "Time", "Tissue Sample", "Tissues", "Vaccines", "Viral", "Viral Antigens", "Viral Load result", "Viral reservoir", "Viremia", "Virus Latency", "Visceral", "acute infection", "adverse outcome", "blood glucose regulation", "clinical care", "clinical diagnosis", "clinical heterogeneity", "comorbidity", "cytokine", "diet-induced obesity", "endothelial dysfunction", "fasting glucose", "glucose metabolism", "glucose tolerance", "glycemic control", "human tissue", "insulin secretion", "insulin tolerance", "islet", "lipid metabolism", "macrophage", "male", "metabolic phenotype", "mortality", "nasal swab", "nonhuman primate", "novel", "obese person", "pandemic disease", "patient population", "pre-clinical", "response", "severe COVID-19", "subcutaneous", "therapy development", "vaccination outcome", "variants of concern", "western diet" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1424, "count": 14236 } } }